Related Experiment Video
Updated: Jun 16, 2025

Author Spotlight: THP-1 Macrophage Response to LPS/ATP — Unveiling the Pyroptosis, Apoptosis, and Necroptosis Spectrum
Published on: May 3, 2024
Reuterin promotes pyroptosis in hepatocellular cancer cells through mtDNA-mediated STING activation and caspase 8
Lin Cui1, Xiaohui Xu1, Hui Fan1
1Department of Biochemistry and Molecular Biology, and Molecular Medicine and Cancer Research Center, College of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400016, China.
Abstract:
Hepatocellular carcinoma (HCC) is the most common form of liver cancer with poor prognosis. The available drugs for advanced HCC are limited and substantial therapeutic advances including new drugs and new combination therapies are still in urgent need. In this study, we found that the major metabolite of Lactobacillus reuteri (L. reuteri), reuterin showed great anti-HCC potential and could help in sorafenib treatment. Reuterin treatment impaired mitophagy and caused the aberrant clustering of mitochondrial nucleoids to block mitochondrial DNA (mtDNA) replication and mitochondrial fission, which could promote mtDNA leakage and subsequent STING activation in HCC cells. STING could activate pyroptosis and necroptosis, while reuterin treatment also induced caspase 8 expression to inhibit necroptosis through cleaving RIPK3 in HCC cells. Thus, pyroptosis was the main death form in reuterin-treated HCC cells and STING suppression remarkably rescued the growth inhibitory effect of reuterin and concurrently knockdown caspase 8 synergized to restrain the induction of pyroptosis. In conclusion, our study explains the detailed molecular mechanisms of the antitumor effect of reuterin and reveals its potential to perform as a combinational drug for HCC treatment.
Insights
Reuterin, a metabolite from Lactobacillus reuteri, shows potential against hepatocellular carcinoma (HCC) by inducing cell death. It may enhance sorafenib treatment for liver cancer.
Area of Science:
- Oncology
- Microbiology
- Immunology
Background:
- Hepatocellular carcinoma (HCC) presents a significant clinical challenge due to limited treatment options and poor prognosis.
- There is a critical need for novel therapeutic strategies, including new drugs and combination therapies, to combat advanced HCC.
Purpose of the Study:
- To investigate the anti-HCC potential of reuterin, a metabolite of Lactobacillus reuteri.
- To elucidate the molecular mechanisms underlying reuterin's anti-tumor effects and its synergy with sorafenib.
Main Methods:
- Assessing reuterin's impact on HCC cell viability and death pathways.
- Analyzing the effects of reuterin on mitophagy, mitochondrial DNA (mtDNA) replication, mitochondrial fission, and STING activation.
- Investigating the roles of caspase 8 and RIPK3 in reuterin-induced cell death.
Main Results:
- Reuterin demonstrated significant anti-HCC potential, impairing mitophagy and mtDNA replication.
- Reuterin induced STING activation, leading to pyroptosis and necroptosis, with pyroptosis being the predominant cell death pathway.
- Reuterin treatment upregulated caspase 8, which cleaved RIPK3, thereby inhibiting necroptosis and promoting pyroptosis.
Conclusions:
- Reuterin exhibits potent anti-cancer properties against HCC by disrupting mitochondrial function and activating STING-mediated cell death.
- Reuterin's mechanism involves promoting pyroptosis as the primary mode of cancer cell death.
- Reuterin holds promise as a combinational therapeutic agent for HCC, potentially enhancing existing treatments like sorafenib.
Related Concept Videos
The Extrinsic Apoptotic Pathway
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The Intrinsic Apoptotic Pathway
Regulation of the Unfolded Protein Response
MAPK Signaling Cascades
Caspases

